Compare FUBO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | IKT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 240.1M |
| IPO Year | 2011 | 2020 |
| Metric | FUBO | IKT |
|---|---|---|
| Price | $11.53 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $28.40 | $5.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.08 | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,271,000.00 | N/A |
| Revenue This Year | $44.64 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10317.07 | N/A |
| 52 Week Low | $1.02 | $1.33 |
| 52 Week High | $14.54 | $2.37 |
| Indicator | FUBO | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 55.52 |
| Support Level | $3.17 | $1.43 |
| Resistance Level | $14.05 | $1.88 |
| Average True Range (ATR) | 0.95 | 0.12 |
| MACD | -0.41 | 0.02 |
| Stochastic Oscillator | 15.32 | 78.12 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.